AstraZeneca CEO Discusses Summit Therapeutics' Drug as a Potential Game-Changer for Cancer Treatment
AstraZeneca CEO Pascal Soriot highlighted Summit Therapeutics’ lead drug, ivonescimab, during an exclusive interview with CNBC. He described it as pivotal in the next generation of cancer treatment combinations that could redefine care standards. The comments followed AstraZeneca’s $2 billion equity investment and clinical collaboration agreement with Summit to explore new therapies. Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF pathways, offering dual action against tumors by boosting the immune response while cutting off their blood supply. Soriot emphasized its potential when combined with AstraZeneca’s own targeted treatments like antibody-drug conjugates. AstraZeneca also announced a new $1 billion R&D facility in Cambridge, Massachusetts, where AI and robotics will accelerate drug development across multiple therapeutic areas.
Topics: biotech investment cancer treatment clinical trials pharma collaboration